Superworth

Charles River Laboratories International price to book ratio CRL

Market value divided by the book value of the company's net assets, since 2010.

Today, Oct 23, 2026
5.8×
10-year median
4.6×
Against its 10-year history
84th
percentile: 0 is its lowest day, 100 its highest
10-year range
1.5× to 10.0×
Peer median
5.0×

Charles River Laboratories International's price to book ratio is 5.8× as of Oct 23, 2026.

That is above its ten-year median of 4.6×, higher than on 84% of days in the last ten years.

Over that time it ranged from 1.5× in Apr 2025 to 10.0× in Sep 2021.

The median for 10 diagnostics and research stocks of a similar size is 5.0×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.8×2.3×5.8×
20252.9×1.5×2.9×
20242.5×2.5×3.9×
20233.7×2.7×4.8×
20224.2×3.6×7.4×
20217.8×6.4×10.0×
20206.6×3.2×7.1×
20194.8×4.2×5.3×
20184.3×4.2×5.5×
20175.1×4.3×5.8×
20164.2×3.7×5.3×
20155.3×4.3×5.9×
20144.5×3.5×4.5×
20133.9×3.2×3.9×
20123.0×2.5×3.5×
20112.5×2.0×3.9×
20102.0×1.4×2.0×

Against its peers

Companies in Medical - Diagnostics & Research nearest Charles River Laboratories International's size, closest first, today.

CompanyPrice to book ratio
CRLCharles River Laboratories International5.8×
RVTYRevvity2.5×
MEDPMedpace43.1×
LHLabcorp3.1×
DGXQuest Diagnostics3.6×
BIOBio-Rad Laboratories1.4×
CAICaris Life Sciences15.3×
MTDMettler-Toledo Internationaln/m
ILMNIllumina14.3×
LNTHLantheus5.0×
IDXXIDEXX Laboratories27.4×
Peer median5.0×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Charles River Laboratories International

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.